Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

HER2 (EGFR2; ErbB2; neu)

Mouse and cell culture studies have identified a HER2-specific aptamer that could help treat HER2+ cancers. In a human gastric cancer cell line, a trimeric version of a HER2-specific aptamer increased lysosome-mediated degradation of HER2 compared with an inactive control oligonucleotide. In a mouse xenograft model for human gastric cancer, the trimeric, HER2-specific aptamer inhibited tumor growth more than an anti-HER2 mAb or an inactive control oligonucleotide. Next steps include testing the trimeric aptamer in combination with approved, HER2-targeting drugs.

SciBX 6(20); doi:10.1038/scibx.2013.489
Published online May 23, 2013

Patent application filed; available for licensing from Yeda Research and Development Co. Ltd., the technology transfer company of the Weizmann Institute of Science
Contact: Amir Naiberg, Weizmann Institute of Science, Rehovot, Israel
e-mail:
amir.naiberg@weizmann.ac.il

Mahlknecht, G. et al. Proc. Natl. Acad. Sci. USA; published online April 29, 2013;
doi:10.1073/pnas.1302594110
Contact: Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel
e-mail:
yosef.yarden@weizmann.ac.il

Contact: Michael Sela, same affiliation as above
e-mail:
michael.sela@weizmann.ac.il